The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Yushi NaitoMasashi KatoHideji KawanishiYuri YuguchiTakuma YubaTomohiro IshikawaKyosuke HattoriAkiyuki YamamotoTomoyasu SanoYoshihisa MatsukawaToru KimuraToshinori NishikimiRyohei HattoriToyonori TsuzukiMomokazu GotohPublished in: The Prostate (2020)
Certain patients with CRPC can benefit from ART-to-ART sequential therapy in a daily clinical setting.